HIV/AIDS HAART
Low-dose ritonavir has a modest inhibitory effect on CYP2D6 in extensive metabolizers
Published in Anti-Infectives Week, February 20th, 2006
"In the treatment of human immunodeficiency virus infection, the protease inhibitor ritonavir is used in a low dose (100 mg twice daily) to inhibit cytochrome P450 (CYP) 3A4 and thereby increase plasma concentrations of coadministered protease inhibitors. When applied in a therapeutic dose (600 mg twice daily), ritonavir also inhibits CYP2D6," scientists in the Netherlands report.
According to R.E. Aarnoutse and colleagues at the University of Nijmegen, "The effect of low-dose ritonavir on CYP2D6 is unknown and was investigated in this study. This was a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
Source: Anti-Infectives Week (2006-02-20)
More Articles from Anti-Infectives Week
- Antimicrobials
Epsilon-polylysine has antimicrobial activity against three common pathogens - Drug Resistance
Pair of studies offer new clues to combat antibiotic resistance - Infection Control
Response algorithm controls transmission of airborne-spread diseases - Toxic Shock Syndrome
Prophylactic antibiotics prevent toxic shock syndrome in burn patients - Tuberculosis Therapy
Acquired resistance and eradication of susceptible bacteria can occur concurrently - Adverse Drug Reaction
Antimicrobial agents can cause drug interactions in children treated for cancer - More from this issue of Anti-Infectives Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
